Fig. 6
From: BTApep-TAT peptide inhibits ADP-ribosylation of BORIS to induce DNA damage in cancer
BTApep-TAT inhibited the progression of xenograft tumors. (A) The experimental schedule of the xenograft tumor and treatment experiments. (B) The growth of the NSCLC xenograft in animals treated with BTApep-TAT was compared with those treated with His-TAT. The left panel shows the changes in the tumor volume during the observation and treatment period. The right panel presents the differencee in the tumor weight between the two treatment groups at the end of the experiment. (C) Hepatic and renal functions after peptide treatments were examined by serum-based tests. (D) The extent of DNA damage was evaluated by TUNEL assays. The left panel shows representative images of the TUNEL assays captured by microscopy, and the right panel shows a statistical summary of the comparison of TUNEL-positive cells between the treatment groups